Switch theme
Sign up to access all valuation multiples
EGEIRO Pharma is a biopharmaceutical company. The company is focused on the clinical development of drugs for Idiopathic Pulmonary Fibrosis, a chronic, devastating, and fatal disease characterized by the deterioration of lung function.
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
EGEIRO Pharma has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, EGEIRO Pharma achieved revenue of $1.2M and an EBITDA of -$0.6M.
EGEIRO Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See EGEIRO Pharma valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $1.2M | n/a | XXX | XXX | XXX |
| Gross Profit | -$0.6M | -$1.1M | XXX | XXX | XXX |
| Gross Margin | -56% | NaN% | XXX | XXX | XXX |
| EBITDA | -$0.6M | n/a | XXX | XXX | XXX |
| EBITDA Margin | -49% | NaN% | XXX | XXX | XXX |
| Net Profit | -$1.4M | -$2.5M | XXX | XXX | XXX |
| Net Margin | -124% | NaN% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, EGEIRO Pharma's stock price is EUR 0 (or $0).
EGEIRO Pharma has current market cap of EUR 10.0M (or $10.8M), and EV of EUR 10.0M (or $10.8M).
See EGEIRO Pharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $10.8M | $10.8M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, EGEIRO Pharma has market cap of $10.8M and EV of $10.8M.
EGEIRO Pharma's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate EGEIRO Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for EGEIRO Pharma and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $10.8M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpEGEIRO Pharma's NTM/LTM revenue growth is n/a
EGEIRO Pharma's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $0.1M for the same period.
Over next 12 months, EGEIRO Pharma's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate EGEIRO Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for EGEIRO Pharma and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.1M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.1M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | 153% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
EGEIRO Pharma acquired XXX companies to date.
Last acquisition by EGEIRO Pharma was XXXXXXXX, XXXXX XXXXX XXXXXX . EGEIRO Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| Where is EGEIRO Pharma headquartered? | EGEIRO Pharma is headquartered in France. |
| How many employees does EGEIRO Pharma have? | As of today, EGEIRO Pharma has 14 employees. |
| Is EGEIRO Pharma publicy listed? | Yes, EGEIRO Pharma is a public company listed on PAR. |
| What is the stock symbol of EGEIRO Pharma? | EGEIRO Pharma trades under ALVET ticker. |
| When did EGEIRO Pharma go public? | EGEIRO Pharma went public in 2021. |
| Who are competitors of EGEIRO Pharma? | Similar companies to EGEIRO Pharma include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of EGEIRO Pharma? | EGEIRO Pharma's current market cap is $10.8M |
| Is EGEIRO Pharma profitable? | Yes, EGEIRO Pharma is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
